{"nctId":"NCT01896232","briefTitle":"Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet","startDateStruct":{"date":"2013-08-13","type":"ACTUAL"},"conditions":["Secondary Hyperparathyroidism","Chronic Kidney Disease"],"count":683,"armGroups":[{"label":"Cinacalcet","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cinacalcet","Drug: Intravenous Placebo"]},{"label":"Etelcalcetide","type":"EXPERIMENTAL","interventionNames":["Drug: Etelcalcetide","Drug: Oral Placebo"]}],"interventions":[{"name":"Etelcalcetide","otherNames":["AMG 416"]},{"name":"Cinacalcet","otherNames":["Sensipar®, Mimpara®"]},{"name":"Oral Placebo","otherNames":[]},{"name":"Intravenous Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Eligible subjects must be receiving adequate thrice weekly maintenance hemodialysis with a dialysate calcium concentration ≥ 2.5 mEq/L for at least 3 months prior to screening laboratory assessments\n* Subjects must have SHPT as defined by one central laboratory screening predialysis serum PTH value \\> 500 pg/mL, measured on separate days within 2 weeks prior to randomization\n* Subjects must have one serum cCa value ≥ 8.3 mg/dL obtained before dialysis within 2 weeks of the date of randomization\n* Subjects receiving calcium supplements must have no more than a maximum dose change of 50% within 2 weeks before screening laboratory assessments are obtained, and the dose must remain unchanged through randomization\n\nExclusion Criteria:\n\n* Eligible subjects cannot have received cinacalcet during the 3 months preceding the first screening laboratory assessment\n* Other criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With > 30% Reduction From Baseline in Mean Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority Analysis","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.9","spread":null},{"groupId":"OG001","value":"77.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With > 50% Reduction From Baseline in Mean PTH During the Efficacy Assessment Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.2","spread":null},{"groupId":"OG001","value":"52.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With > 30% Reduction From Baseline in Mean PTH During the Efficacy Assessment Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.7","spread":null},{"groupId":"OG001","value":"68.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Number of Days of Vomiting or Nausea Per Week in the First 8 Weeks","description":"Participants completed the Nausea/Vomiting Symptom Assessment (NVSA) questionnaire daily. This questionnaire asked participants to indicate the severity of nausea on a scale from 0 (no nausea) to 10 (as severe as can be imagined) and if they had vomited in the past 24 hours. A day of vomiting or nausea was defined as those where the severity of nausea score was \\> 0 or where the episodes of vomiting score was \\> 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.03"},{"groupId":"OG001","value":"0.4","spread":"0.04"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Mean Corrected Calcium During the Efficacy Assessment Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.28","spread":"0.44"},{"groupId":"OG001","value":"-9.83","spread":"0.49"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Mean Predialysis Serum Phosphorus ≤ 4.5 mg/dL During the Efficacy Assessment Phase","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.2","spread":null},{"groupId":"OG001","value":"32.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Severity of Nausea in the First 8 Weeks","description":"Severity of nausea was assessed using the Nausea and Vomiting Symptom Assessment questionnaire which asked participants to rate the severity of nausea on a scale from 0 (no nausea) to 10 (as severe as can be imagined). For each participant, the mean severity of nausea was calculated by averaging all available daily severities (including zeroes) reported in the first 8 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":"0.06"},{"groupId":"OG001","value":"0.45","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Mean Number of Episodes of Vomiting Per Week in the First 8 Weeks","description":"The number of vomiting episodes was assessed using the Nausea and Vomiting Symptom Assessment questionnaire which asks participants on a daily basis how many times they vomited in the past 24 hours. The number of episodes in a week is the sum of all reported daily episodes in the week.\n\nFor participants providing less than 7 days of responses to NVSA questions in any given week, data from that week did not contribute to the analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.02"},{"groupId":"OG001","value":"0.2","spread":"0.02"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":93,"n":341},"commonTop":["Blood calcium decreased","Nausea","Vomiting","Diarrhoea","Headache"]}}}